FONT-SIZE Plus   Neg

Foundation Medicine And Clovis Oncology Enter Into Diagnostic Collaboration

Foundation Medicine Inc. and Clovis Oncology Inc. (CLVS) announced that they have entered into a diagnostic collaboration. The company said that the goal of the collaboration is to develop an in-vitro diagnostic or IVD to identify biomarkers to select cancer patients most likely to respond to Clovis' product candidate rucaparib, a poly (ADP-ribose) polymerase or PARP inhibitor currently in Phase I/II clinical development.

Clovis Oncology said that the company and Foundation Medicine will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Boeing Co. (BA) reported a profit for the third-quarter climbed 34 percent from the the previous year, reflecting overall solid execution on production programs and services, favorable tax items, and timing of aircraft deliveries. The company raised its 2016 financial and delivery guidance reflecting higher commercial deliveries and the impact of the tax basis adjustment. GlaxoSmithKline PLC (GSK.L, GSK) reported that its third-quarter core operating profit was 2.32 billion pounds, 13% higher in CER terms than in prior year. Core earnings per share for the quarter was up 12% CER to 32.0 pence. Total basic earnings per share was 16.6 pence, down 1% CER, primarily reflecting... Coca-Cola Co. (KO) reported a profit for the third-quarter that declined 28 percent from the prior year. Net revenues were down 7% from prior year, impacted by a foreign currency exchange headwind of 2% and a headwind from acquisitions, divestitures and structural items of 8%. The company reaffirmed organic revenue and comparable earnings per share outlook for fiscal year 2016.
comments powered by Disqus
Follow RTT